GlassScriptPhysician profile
Kane Ethan Edwards
NPI 1851853436
$4,574.81
in general payments reported to CMS, 2019-2025
32 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.12 · 2020: $40.62 · 2021: $124 · 2022: $141 · 2023: $1,130 · 2024: $1,103 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,082 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,082.13 |
| Education | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,249.68 | 2020-2025 | Rinvoq, Skyrizi, Viberzi |
| Janssen Biotech, INC. | $668.56 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $460.87 | 2022-2025 | Entyvio, Gattex, Livtencity |
| Genzyme Corporation | $253.52 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $200.33 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.19 | 2021-2025 | Xifaxan, Trulance |
| Conmed Corporation | $169.17 | 2023 | Conmed Biliary, Conmed Hemostasis, Conmed Generators |
| Gilead Sciences, INC. | $158.06 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $123.03 | 2023-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $113.63 | 2023 | Zeposia |
| Lilly USA, LLC | $105.88 | 2024-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $104.35 | 2025 | Tremfya |
| Pfizer INC. | $97.34 | 2024-2025 | |
| Madrigal Pharmaceuticals | $81.79 | 2025 | Rezdiffra |
| Mahana Therapeutics, INC. | $72.97 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $72.62 | 2022-2025 | Ocaliva |
| Celgene Corporation | $64.81 | 2023-2024 | Zeposia |
| Ardelyx, INC. | $62.39 | 2023-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $60.62 | 2024-2025 | Iqirvo |
| Fujifilm Healthcare Americas Corporation | $53.81 | 2025 | |
| Boston Scientific Corporation | $28.67 | 2025 | Axonics |
| Daiichi Sankyo INC. | $23.80 | 2024 | Injectafer |
| Exact Sciences Corporation | $18.36 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $16.96 | 2023 | Dificid |
| Evoke Pharma, INC. | $16.89 | 2024 | |
| Fresenius Kabi USA, LLC | $15.51 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.23 | 2024 | Cyltezo |
| Braintree Laboratories, INC. | $14.58 | 2024 | Sutab, Suflave |
| Janssen Pharmaceuticals, INC | $14.08 | 2020 | |
| Organon LLC | $13.59 | 2023 | |
| Novo Nordisk INC | $13.40 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kane Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.